protein
influenza
protong
proton
channel
requir
viral
replic
current
influenza
strain
resist
licens
antivir
new
therapi
target
need
structur
function
rise
drug
resist
mutat
current
antivir
strategi
discuss
ongo
threat
season
pandem
influenza
human
health
requir
antivir
effect
supplement
exist
vaccin
strategi
protein
influenza
viru
iav
protong
protonselect
ion
channel
requir
viru
replic
establish
antivir
target
licens
adamantanebas
antivir
histor
use
mutat
confer
major
adamantan
resist
preval
circul
viru
strain
drug
longer
recommend
review
current
understand
iav
structur
function
mechan
inhibit
rise
drug
resist
mutat
ongo
effort
develop
new
antivir
target
resist
form
influenza
viru
iav
signific
ongo
caus
human
morbid
mortal
worldwid
prophylact
vaccin
confer
immun
circul
viru
strain
effect
extent
immun
coverag
vari
across
popul
year
year
variabl
contribut
part
recent
notabl
season
outbreak
estim
center
diseas
control
prevent
caus
approxim
hospit
death
unit
state
alon
cdc
rolf
et
al
particular
concern
less
common
histor
regular
pandem
outbreak
popul
limit
immun
result
hundr
thousand
million
death
worldwid
moreov
still
remain
signific
technic
gap
expedit
rapid
vaccin
product
respons
particularli
face
increasingli
global
spread
newlyemerg
viru
strain
renaud
et
al
hurt
thu
addit
countermeasur
iav
form
prophylact
therapeut
antivir
continu
need
protein
requir
iav
replic
spread
establish
antivir
target
protong
proton
channel
belong
grow
viroporin
famili
viru
protein
ion
channel
activ
requir
iav
replic
adamantanebas
inhibitor
includ
amantadin
rimantadin
figur
histor
use
influenza
antivir
howev
adamantaneresist
viru
strain
preval
point
drug
longer
recommend
therapeut
use
bright
et
al
deyd
et
al
fior
et
al
hayden
de
jong
circul
adamantaneresist
virus
harbor
serin
asparagin
mutat
amino
acid
posit
bright
et
al
distort
adamantan
interact
within
pore
without
significantli
affect
ion
channel
activ
fit
viral
replic
gramba
et
al
pinto
et
al
stouffer
et
al
therefor
major
goal
current
studi
identifi
new
inhibitor
adamantaneresist
recent
advanc
molecular
structur
biolog
electrophysiolog
virolog
produc
crucial
inform
basi
drug
resist
turn
shed
light
novel
drug
develop
strategi
transit
idea
practic
tool
review
current
state
iav
viroporin
research
ongo
effort
identifi
develop
new
antivir
drugresist
form
viroporin
small
often
amino
acid
virallyencod
transmembran
protein
regul
ion
conduct
across
lipid
membran
frequent
featur
rna
dna
virus
nieva
et
al
nietotorr
ouyang
chou
viroporin
frequent
describ
exhibit
channelpor
dualism
sequenc
broadli
permeabl
ion
small
molecul
other
tightlyregul
channel
conduct
specif
ion
although
function
viroporin
well
understood
gener
involv
conduct
ion
facilit
viral
entri
assembl
andor
releas
host
cell
tabl
list
viroporin
repres
virus
protein
iav
arguabl
best
understood
viroporin
consist
amino
acid
type
transmembran
domaincontain
protein
form
tetramer
ion
channel
protong
protonselect
hong
degrado
nietotorr
et
al
multifunct
modular
protein
segment
perform
one
distinct
function
wang
et
al
follow
viral
entri
express
virion
membran
transport
proton
host
cell
endosom
acidifi
virion
interior
figur
low
ph
environ
facilit
conform
chang
viral
hemagglutinin
ha
dissoci
viral
ribonucleoprotein
complex
protein
promot
virion
membran
fusion
releas
viral
rna
host
cell
proton
gate
function
howev
requir
per
se
convert
ha
membran
fusion
compet
state
bui
et
al
gutman
et
al
martin
heleniust
viral
egress
also
equilibr
ph
transgolgi
lumina
cytoplasm
may
delay
traffick
virion
particl
andor
prevent
ha
inappropri
adopt
low
ph
conform
alvaradofacundo
et
al
ciampor
et
al
li
et
al
pinto
lamb
sugru
et
al
compar
influenza
protein
sequenc
highli
conserv
shown
coevolv
ha
gramba
et
al
rossman
lamb
conduct
rate
close
correl
ha
fusogen
propens
increas
proton
conduct
correl
acid
labil
ha
sequenc
gramba
hay
scholtissek
et
al
also
found
local
viru
bud
site
host
cell
surfac
amphipath
helix
alter
membran
curvatur
lead
membran
scission
releas
new
viral
progeni
chen
et
al
rossman
lamb
rossman
et
al
although
proton
prefer
substrat
also
act
na
k
antiport
leid
et
al
particular
abil
pass
bulkier
k
ion
becom
physiolog
relev
endocyt
pathway
high
na
concentr
earli
endosom
cluster
replac
k
allow
subsequ
releas
viral
ribonucleoprotein
bundl
stauffer
et
al
exist
initi
report
lamb
et
al
lai
pinto
et
al
xenopu
laevi
oocyt
inject
rna
measur
twoelectrod
voltag
clamp
tevc
method
electrophysiolog
becom
common
assay
far
measur
conduct
inhibit
small
molecul
howev
sever
group
use
varieti
electrophysiolog
techniqu
includ
wholecel
patchclamp
mammalian
cell
probe
ion
conduct
properti
chizhmakov
et
al
holsing
et
al
holsing
et
al
jalili
et
al
shimbo
et
al
tu
et
al
wang
et
al
wang
et
al
exampl
chizhmakov
et
al
express
mous
erythroleukemia
cell
also
observ
select
conduct
proton
subsequ
mutagenesi
studi
defin
specif
amino
acid
residu
requir
proton
conduct
regul
figur
notabl
fragment
encompass
transmembran
domain
span
littl
amino
acid
observ
tevc
suffici
produc
amantadinesensit
protondepend
proton
current
first
approxim
transmembran
mutat
predict
increas
pore
radiu
ie
mutat
residu
smaller
side
chain
result
increas
proton
conduct
presum
either
enhanc
format
water
wire
transfer
conform
chang
mutat
residu
bulkier
side
chain
reduc
pore
radiu
also
reduc
conduct
exampl
introduct
ala
face
extracellular
intralumin
surfac
thought
form
constrict
part
channel
increas
pore
entranc
size
obliter
ntermin
gate
mechan
therebi
allow
easier
pore
hydrat
enhanc
conduct
holsing
et
al
pielak
chou
contrast
introduct
bulki
andor
hydrophob
residu
phe
trp
result
nonor
lowconduct
protein
similarli
mutat
reduc
pore
size
locat
includ
also
slow
rate
proton
conduct
frequent
result
lossoffunct
notabl
highlyconserv
sequenc
within
ctermin
end
transmembran
domain
regard
function
core
proton
conduct
pinto
lamb
tang
et
al
venkatraman
et
al
mutat
gli
gln
result
enhanc
conduct
also
loss
proton
select
andor
lack
ph
depend
wang
et
al
moreov
mutat
ala
cy
phe
result
larger
inward
current
also
outward
current
indic
regul
unidirect
conduct
tang
et
al
anoth
key
residu
like
face
pore
interior
mutat
hydrophob
residu
ala
neg
affect
pore
hydrat
result
diminish
conduct
end
histrp
quartet
mutat
hydrophob
residu
ala
affect
proton
exit
ctermin
end
channel
increas
energi
barrier
mutat
might
also
impact
function
indirectli
affect
inher
conduct
moieti
defin
tetrad
gate
mechan
defin
gu
et
al
recent
report
structur
instrument
toward
understand
adamantan
inhibit
ion
channel
drug
resist
overcom
addit
gener
inform
new
drug
discoveri
ion
channel
biolog
experimentallydetermin
protein
structur
deriv
xray
crystallographi
solidst
solut
nuclear
magnet
reson
nmr
proteinligand
complex
structur
origin
comput
studi
also
form
basi
structurebas
drug
design
write
structur
wildtyp
wt
drugresist
protein
avail
protein
data
bank
pdb
solv
xray
techniqu
although
elucid
use
nmr
mechan
proton
shuttl
enabl
conduct
remain
incomplet
understood
like
experiment
condit
ph
peptid
length
lipiddeterg
composit
thick
bind
small
molecul
affect
fundament
properti
acharya
et
al
cadi
et
al
du
et
al
kolokouri
et
al
kovac
et
al
thomaston
et
al
zhou
cross
among
avail
structur
pdb
among
first
structur
solv
use
solut
nmr
xray
crystallographi
micel
respect
schnell
chou
stouffer
et
al
hu
et
al
sharma
et
al
subsequ
appli
solid
state
nmr
molecular
dynam
explor
activ
conduct
mechan
low
ph
use
pdb
entri
cadi
et
al
sharma
et
al
although
studi
support
protonrelay
model
conduct
differ
regard
sidechain
conform
studi
hu
et
al
propos
tightlypack
tetrad
undergo
numer
reorient
side
chain
rotat
relay
proton
contrast
model
sharma
et
al
suggest
three
distinct
state
histrp
quartet
histidinelock
state
activ
state
conduct
state
transit
state
allow
proton
conduct
model
histidin
lock
state
exist
proton
share
two
adjac
histidin
residu
hish
channel
lock
nonconduct
state
describ
activ
cascad
low
extracellular
ph
singl
hydronium
ion
approach
nonproton
histidin
hish
dimer
break
ionic
bond
transit
channel
activ
state
result
format
stabl
cationp
interact
tetrad
form
gate
ctermin
end
perturb
cationp
interact
lead
conform
chang
turn
transit
quartet
conduct
state
proton
donat
water
molecul
relay
intracellular
side
figur
transit
three
step
requir
small
chang
angl
side
chain
contrast
model
hu
et
al
consider
reorient
residu
requir
allow
proton
passag
experiment
theoret
data
support
model
describ
detail
elsewher
hong
degrado
thomaston
et
al
watkin
et
al
zhou
cross
ion
channel
activ
wt
effect
antagon
two
fdaapprov
adamantaneclass
drug
amantadin
rimantadin
figur
addit
numer
adamantan
nonadamantan
deriv
tabl
tataridi
et
al
wang
et
al
wang
et
al
wu
et
al
viru
entri
amantadin
inhibit
result
incomplet
dissoci
ribonucleoprotein
complex
turn
fail
enter
nucleu
initi
replic
also
equilibr
ph
across
transgolgi
network
cytoplasm
amantadinebas
inhibit
may
also
disrupt
viral
egress
lamb
ra
krug
takeda
et
al
amantadin
first
obtain
fda
approv
brand
name
symmetrel
system
use
human
prophylaxi
asian
influenza
davi
et
al
schwab
et
al
wingfield
et
al
howev
first
decad
follow
licensur
symmetrel
wide
prescrib
due
part
side
effect
agit
confus
hallucin
keyser
et
al
addit
molecular
mechan
describ
direct
link
amantadin
viru
inhibit
describ
year
later
duff
ashley
pinto
et
al
rimantadin
sold
brand
name
flumadin
methyl
deriv
amantadin
licens
fda
indic
two
pharmacolog
relev
bind
mechan
initi
propos
adamantan
figur
first
report
crystallograph
structur
amantadin
ph
pdb
stouffer
et
al
suggest
amantadin
bind
pocket
locat
insid
intralumin
caviti
surround
nonpolar
side
chain
c
group
c
group
figur
pore
bind
model
author
propos
amantadin
enter
lumen
channel
plug
pore
thu
prevent
transport
proton
model
suggest
confer
adamantan
resist
decreas
pore
size
occlud
stabl
access
amantadin
pore
stouffer
et
al
separ
seri
studi
altern
initi
controversi
bind
mechan
adamantan
locat
extern
pore
also
propos
pielak
et
al
schnell
chou
figur
studi
rimantadin
found
bind
ctermin
lipidfac
side
helic
solut
nmr
structur
pdb
solv
ph
show
alloster
mechan
inhibit
four
drug
molecul
propos
stabil
inactiv
state
therebi
prevent
protong
open
proton
transfer
bind
mechan
perturb
extralumin
drug
bind
pocket
result
mutat
render
rimantadin
incap
effect
bind
alloster
site
pielak
et
al
reconcil
find
seri
experiment
comput
studi
rapidli
report
jing
et
al
balannik
et
al
cadi
et
al
carpent
et
al
chuang
et
al
stouffer
et
al
jing
et
al
demonstr
intralumin
bind
site
physiolog
relev
conduct
wholecel
electrophysiolog
antivir
assay
use
mutant
chimer
form
mutat
critic
residu
alanin
jing
cowork
continu
observ
inhibit
amantadin
electrophysiolog
antivir
plaqu
assay
suggest
allostericbind
site
pharmacolog
essenti
jing
et
al
addit
chimer
ion
channel
base
influenza
b
normal
amantadineinsensit
due
larger
hydrophil
transmembran
pore
mould
et
al
substitut
transmembran
domain
influenza
restor
amantadin
sensit
jing
et
al
use
solidst
nmr
cadi
et
al
also
report
channel
pore
prefer
bind
site
pdb
amantadin
preferenti
local
hydrophob
cage
form
hydrophob
interact
side
chain
adamantan
cage
also
observ
ammonium
group
amantadin
show
hydrogen
bond
water
molecul
porefac
residu
stabil
interact
occlud
pore
author
also
report
interact
alloster
bind
site
observ
high
amantadin
concentr
thu
less
probabl
primari
mode
inhibit
support
porebind
model
mutat
propos
key
residu
alloster
bind
mechan
six
differ
amino
acid
affect
inhibit
amantadin
notabl
test
initi
hypothesi
alloster
bind
site
amantadin
next
gener
chimera
cterminu
deriv
amantadineinsensit
influenza
b
viru
pdb
contrari
previous
propos
alloster
bind
mechan
use
solut
nmr
describ
rimantadin
bind
pocket
preserv
within
pore
chimer
protein
seri
surfac
plasmon
reson
experi
porebind
site
also
found
energet
favor
alloster
bind
site
although
latter
remain
sensit
amantadin
rosenberg
casarotto
anoth
comput
studi
use
small
molecular
probe
solvent
map
techniqu
found
porebind
site
energet
favor
although
alloster
site
also
observ
condit
chuang
et
al
gu
et
al
also
appli
molecular
dynam
approach
studi
antagonist
effect
known
inhibitor
observ
interact
porebind
site
thermodynam
stabl
ligand
bound
slowli
poorli
dissoci
due
high
energi
barrier
bind
contrast
alloster
bind
readili
access
energi
barrier
bind
minim
drug
bind
less
stabl
readili
dissoci
moreov
initi
nmr
structur
pdb
show
evid
intralumin
bind
site
rather
bind
alloster
peripher
site
lipid
interfac
howev
also
interpret
note
nmr
structur
narrow
compar
counterpart
xray
structur
pdb
due
smaller
tilt
angl
result
transmembran
helic
overli
parallel
find
alert
field
import
protein
crystal
environ
emphasis
risk
crystal
pack
distort
across
publish
crystal
structur
later
synthes
organosilan
probe
measur
intermolecular
noesi
spectra
dpc
micel
wang
et
al
also
map
drug
bind
site
ntermin
lumen
near
recent
highresolut
xray
crystal
structur
complex
adamantan
channel
blocker
publish
degrado
lab
also
unambigu
recogn
intralumin
bind
site
thomaston
et
al
taken
togeth
followup
studi
support
amantadin
inhibit
iav
plug
pore
figur
recent
bind
affin
r
enantiom
rimantadin
also
question
surprisingli
compar
isotrop
chemic
shift
chang
rimantadin
two
enantiom
ssnmr
experi
molecular
dynam
simul
wright
et
al
propos
enantiom
may
bind
fulllength
differenti
higher
affin
rel
enantiom
howev
subsequ
seri
vitro
cellular
assay
electrophysiolog
experi
molecular
dynam
simul
indic
enantiom
exhibit
similar
channel
blockad
tevc
experi
compar
antivir
activ
plaqu
assay
similar
free
energi
bind
isotherm
titrat
calorimetri
comput
simul
drakopoulo
et
al
latter
observ
also
consist
experiment
data
show
similar
efficaci
two
enantiom
mice
aldrich
et
al
addit
consist
porebind
model
describ
mutat
also
confer
adamantan
resist
bright
et
al
cadi
et
al
cadi
et
al
largescal
sequenc
analys
circul
iav
strain
indic
three
major
adamantaneresist
mutat
found
transmiss
virus
furus
et
al
furus
et
al
among
preval
mutat
adamantaneresist
strain
dong
et
al
nelson
et
al
although
recent
studi
report
potenti
rise
frequenc
viru
strain
contain
doubl
mutat
durrant
et
al
recent
crystallographi
studi
report
elimin
hydrophob
contact
essenti
adamantan
drug
bind
underli
caus
behind
adamantan
resist
mutant
thomaston
et
al
contrast
singl
mutat
result
complet
resist
amantadin
sequenc
contain
still
inhibit
amantadin
vitro
albeit
approxim
higher
concentr
tevc
experi
plaqu
reduct
assay
pra
substanti
higher
therapeuticallyachiev
wang
et
al
notabl
mutat
isol
curat
viru
strain
circul
use
adamantan
preval
mutat
wild
may
exclus
result
drug
select
pressur
contrast
mutat
appear
like
evolv
result
drug
select
pressur
furus
et
al
furus
et
al
effect
mutat
pore
size
proton
conduct
elucid
exquisit
detail
exampl
solut
nmr
structur
pdb
schnell
chou
present
two
alphahelic
mutat
larger
asparagin
expand
pore
creat
kink
monom
would
expect
result
higher
conduct
contrast
crystal
structur
pdb
stouffer
et
al
show
face
pore
mutat
asparagin
decreas
pore
size
would
expect
reduc
conduct
howev
holsing
et
al
observ
differ
rate
proton
conduct
due
mutat
measur
singl
electrod
electrophysiolog
record
result
confirm
balannik
et
al
twoelectrod
voltag
clamp
assay
mutant
indistinguish
specif
conduct
wt
regardless
locat
pore
line
residu
mutat
like
alter
diamet
well
polar
dynam
channel
pore
result
chang
observ
interact
channel
amantadin
compar
wt
gleed
et
al
interestingli
solv
xray
crystal
structur
contain
mutat
pdb
thomaston
degrado
thomaston
et
al
absenc
drug
molecul
pore
inward
open
state
found
face
pore
stabil
hbond
form
carbonyl
group
neighbor
figur
arrang
steric
constrict
adamantan
bind
site
pore
contrast
inward
close
state
tuck
away
centr
pore
stabil
form
hbond
carbonyl
monomermonom
interfac
therebi
twist
helic
narrow
pore
near
bind
site
figur
altern
use
solut
nmr
structur
demonstr
carboxamid
could
stabil
porefac
conform
bident
interact
inhibitor
compound
tabl
figur
observ
emphas
orient
pore
depend
conform
state
protein
andor
presenc
interact
drug
molecul
lumen
pore
extens
combin
molecular
dynam
simul
khurana
et
al
wang
et
al
xray
crystallographi
acharya
et
al
stouffer
et
al
nmr
spectroscopi
wang
et
al
wang
et
al
wang
et
al
along
iter
cycl
medicin
chemistri
electrophysiolog
test
antivir
assay
led
discoveri
sever
class
compound
inhibit
least
one
three
major
drugresist
mutat
efficaci
compar
better
amantadin
wt
sever
compound
report
throughout
literatur
inhibit
virus
mechan
action
mani
confirm
mediat
mani
compound
test
assay
promis
compound
therefor
valid
antivir
conduct
assay
vast
major
assess
tevc
secondgener
inhibitor
drugresist
broadli
categor
two
main
group
adamantan
tabl
seri
chemic
divers
nonadamantan
molecul
tabl
numer
compound
report
mani
group
addit
cite
tabl
highlight
particular
compound
electrophysiolog
base
ic
prabas
ec
low
submicromolar
concentr
approxim
activ
amantadin
rimantadin
assay
wildtyp
clearli
efficaci
given
inhibitor
measur
tevc
pra
necessarili
translat
efficaci
vivo
howev
subset
inhibitor
recent
advanc
preclin
anim
efficaci
studi
promis
result
report
addit
compound
inhibit
wt
addit
earli
weaker
inhibitor
review
elsewher
duqu
et
al
wang
et
al
among
mani
molecul
synthes
test
degrado
group
compound
confer
drug
resist
mutat
also
coobserv
occasion
mutat
revert
back
upon
drug
withdraw
contrast
passag
dual
inhibitor
compound
result
mutat
also
revert
drug
withdraw
et
al
set
mutat
confirm
resist
respect
select
drug
tevc
result
substanti
reduc
proton
conduct
viral
replic
observ
may
suggest
viabl
evolutionari
space
respons
select
compound
may
limit
resist
studi
compound
also
report
potent
inhibitor
tevc
inhibit
although
propos
slowbind
kinet
may
underestim
efficaci
vitro
viru
replic
ec
low
interestingli
significantli
chang
proton
conduct
amantadin
sensit
wt
howev
presenc
mutat
render
compound
ineffect
tevc
experi
molecular
model
molecular
dynam
simul
author
propos
despit
locat
outsid
canon
bind
site
adamantan
could
affect
size
pore
compound
propos
interact
musharrafieh
et
al
taken
togeth
result
suggest
compar
amantadin
wt
genet
barrier
drug
resist
like
higher
adamantanederiv
compound
target
least
vitro
preclin
vivo
potenti
adamantan
deriv
begin
elucid
exampl
compound
report
inhibit
viru
strain
resist
licens
neuramindas
inhibitor
oseltamivir
hu
et
al
et
al
wang
et
al
oseltamivirsensit
virus
also
synerg
oseltamivir
rais
possibl
combin
therapi
lower
dose
drug
use
minim
risk
toxic
without
sacrif
antivir
efficaci
et
al
wang
et
al
compound
also
exhibit
favor
vitro
pharmacokinet
properti
halflif
least
minut
mous
human
liver
microsom
stabil
assay
also
exhibit
good
cellular
permeabl
cell
x
cm
inhibit
panel
five
cyp
enzym
addit
adamantanederiv
inhibitor
shown
similar
support
preclin
result
indic
properti
fairli
common
chemic
class
furthermor
inject
mice
dualinhibitor
compound
mgkgday
result
chang
bodi
weight
importantli
mgkgday
compound
also
rescu
mice
lethal
infect
virus
contain
either
wt
therebi
demonstr
vivo
efficaci
hu
et
al
initi
result
encourag
vivo
result
adamantan
deriv
remain
limit
await
studi
sever
nonadamantan
chemic
scaffold
also
success
explor
abil
block
adamantaneresist
exampl
nonadamantan
inhibit
drugresist
shown
tabl
polycycl
pyrrolidin
separ
endeavor
deriv
spiranamin
also
explor
wang
et
al
exampl
silaspiran
deriv
exhibit
activ
wt
inhibit
tevc
experi
wang
et
al
anoth
notabl
explor
chemic
class
exemplifi
hexamethylen
amilorid
hma
amiloridebas
compound
report
block
viroporin
andor
replic
iav
hepat
c
viru
dengu
viru
sever
acut
respiratori
syndrom
viru
sarscov
gazina
petrou
pervushin
et
al
premkumar
et
al
howev
hma
sever
offtarget
effect
cytotox
low
micromolar
concentr
jalili
et
al
premkumar
et
al
recent
seri
hma
deriv
design
iter
medicin
chemistri
electrophysiolog
test
approach
jalili
et
al
among
compound
exhibit
activ
wt
singl
electrod
voltag
clamp
sevc
experi
compar
amantadin
studi
ic
vs
obvious
toxic
cell
found
activ
wt
elong
deriv
exhibit
dualinhibitori
effect
wt
sevc
respect
ic
pra
respect
ec
addit
compound
although
inhibit
wt
lower
efficaci
inhibit
sevc
effect
inhibit
virus
encod
wt
pra
ec
respect
preliminari
data
indic
exhibit
stabil
human
microsom
assay
minut
mous
plasma
follow
inject
vivo
minut
moreov
inject
compound
mgkg
affect
monitor
ecg
hemodynam
paramet
mice
cumul
dose
cours
hour
caus
obviou
cardiac
toxic
p
jalili
tietjen
pourrier
fedida
unpublish
data
inhibitori
effect
cu
conduct
initi
studi
gandhi
et
al
show
inhibit
bidirect
across
membran
depend
presenc
wt
protein
also
exhibit
high
specif
cu
partial
inhibit
high
concentr
mm
bival
nickel
zinc
platinum
gandhi
et
al
recent
gordon
et
al
report
discoveri
dival
copper
complex
compound
nonselect
inhibitor
author
propos
mechan
action
copper
complex
independ
mutat
instead
depend
conduct
moieti
inhibit
observ
mutant
compound
abl
inhibit
proton
current
measur
tevc
ec
encod
pra
final
jang
et
al
report
monoval
ionophor
salinomycin
abl
counteract
proton
conduct
function
influenza
b
vitro
howev
indirectli
inhibit
channel
function
prevent
cellular
endosom
acidif
similar
mechan
chloroquin
salinomycin
inhibit
proton
conduct
wt
incorpor
viruslik
particl
vs
wt
um
addit
proton
conduct
highli
diverg
channel
influenza
b
salinomycin
also
synerg
oseltamivir
vitro
howev
salinomycin
exhibit
limit
antivir
activ
vivo
rescu
mice
treat
suboptim
concentr
oseltamivir
lethallyinfect
oseltamivir
sensit
resist
virus
jang
et
al
twoelectrod
voltag
clamp
assay
remain
effect
assay
ion
channel
studi
less
technic
demand
like
replic
across
independ
laboratori
group
compar
sevc
gener
liner
correl
percentag
channel
blockag
tevc
antivir
activ
li
et
al
howev
also
note
efficaci
certain
inhibitor
measur
tevc
pra
discord
howev
kinet
measur
labor
intens
often
reserv
secondari
assay
character
lead
candid
alreadi
shown
potent
antivir
activ
compound
nevertheless
understand
lack
straight
linear
correl
result
vitro
tevc
sevc
assay
cellular
cpe
pra
assay
might
also
addit
due
factor
compound
membran
permeabl
viru
strain
differ
offtarget
effect
howev
specif
issu
relat
channel
blocker
per
se
drug
candid
commonli
face
challeng
well
case
discord
also
extend
protein
virus
contain
differ
mutat
exampl
compound
inhibit
lower
ic
wt
respect
ec
pra
opposit
ie
respect
similar
result
also
seen
compound
could
reflect
exampl
differ
viru
strain
use
andor
subtl
chang
bind
kinet
compound
differ
form
thu
drug
develop
effort
interpret
specif
result
individu
compound
must
perform
care
casebycas
basi
advent
improv
electrophysiolog
techniqu
substanti
advanc
abil
directli
measur
membran
current
singl
cell
express
viroporin
interest
optim
method
includ
tevc
sevc
also
allow
us
studi
fundament
biophys
properti
variant
small
molecul
engag
inhibit
channel
howev
inher
limit
tradit
electrophysiolog
low
throughput
technic
demand
inaccess
techniqu
mani
research
group
larg
restrict
screen
discoveri
novel
inhibitor
special
laboratori
toward
address
limit
recent
develop
system
capac
potenti
autom
electrophysiolog
screen
could
substanti
reduc
time
complex
cost
associ
manual
tradit
patch
clamp
experi
particularli
context
sevc
notabl
compani
sophion
qpatch
nanion
patchlin
fluxion
ionflux
develop
autom
system
screen
ten
hundr
compound
could
principl
perform
sevc
one
day
priest
et
al
enabl
highthroughput
screen
inhibitor
readi
avail
research
group
cerevisia
yeast
strain
also
develop
induc
express
wt
adamantaneresist
protein
presenc
galactos
assay
express
inhibit
yeast
growth
measur
cultur
turbid
turn
restor
administr
inhibitor
shown
balgi
roberg
amantadin
restor
growth
yeast
express
wt
control
assay
optim
high
throughput
screen
exampl
author
subsequ
screen
compound
identifi
new
potent
inhibitor
wt
balgi
et
al
report
demonstr
growth
restor
assay
sensit
econom
technic
simpl
techniqu
high
throughput
screen
inhibitor
presum
viroporin
similar
express
system
use
e
coli
also
use
assess
properti
random
mutat
santner
et
al
although
result
assay
consist
agre
result
obtain
tevc
musharrafieh
et
al
santner
et
al
separ
approach
incorpor
viruslik
particl
proton
conduct
measur
use
potentiometr
fluoresc
dye
readout
sulli
et
al
use
technolog
author
success
screen
compound
format
discov
new
wtspecif
inhibitor
ic
valu
rang
nm
sulli
et
al
although
inhibitor
identifi
target
drug
resist
mutant
design
drug
viral
target
inher
challeng
higher
degre
structur
flexibl
exhibit
viral
protein
comparison
mani
prokaryot
eukaryot
target
da
et
al
fischer
hsu
yet
anoth
challeng
impos
ration
drug
design
depend
highli
flexibl
protein
surround
environ
turn
affect
function
contrast
thermost
protein
encompass
tight
hydrophob
core
viral
protein
frequent
loos
pack
result
smaller
differ
energi
level
fold
unfold
state
also
reduc
contribut
random
mutat
interact
chemic
inhibitor
overal
stabil
paciaroni
et
al
equip
virus
enorm
adapt
mechan
buffer
deleteri
effect
random
mutat
even
case
rna
virus
intrins
mutat
faster
dna
virus
tokuriki
et
al
challeng
also
appli
recent
lack
highresolut
structur
imped
advanc
ration
drug
design
obstacl
prevent
success
design
univers
inhibitor
includ
constrict
drug
bind
site
technic
difficulti
effect
measur
drug
inhibit
absenc
reliabl
protocol
assess
protein
drug
interact
overcom
challeng
comput
play
critic
role
field
ration
drug
design
comput
suffici
process
power
run
virtual
screen
larg
chemic
librari
multipl
target
strategi
identifi
multipl
antivir
lead
includ
put
viroporin
inhibitor
radosev
et
al
tietjen
et
al
likelihood
falseposit
hit
necessit
valid
experiment
techniqu
anoth
role
comput
extend
abil
run
complex
molecular
dynam
simul
shorter
time
larger
complex
predict
visual
interact
viral
protein
domain
put
inhibitor
complex
protein
simul
complex
viral
protein
cellular
factor
taken
togeth
sever
emerg
technolog
avail
design
assess
efficaci
activ
novel
inhibitor
howev
import
note
tevc
pra
remain
gold
standard
studi
appli
secondari
assay
rule
fals
posit
obtain
higherthroughput
method
next
influenza
viru
pandem
albeit
unpredict
matter
new
therapeut
especi
distinct
current
antivir
abil
inhibit
exist
drugresist
viral
strain
may
essenti
toward
mitig
next
inevit
outbreak
viroporin
protondepend
proton
channel
requir
viru
entri
egress
histor
effect
antivir
target
drug
like
amantadin
rimantadin
howev
mutat
particularli
line
pore
adamantan
interact
widespread
render
therapi
ineffect
past
decad
new
inhibitor
drugresist
consist
adamantan
deriv
new
chemic
scaffold
found
inhibit
ion
conduct
demonstr
use
electrophysiolog
techniqu
vitro
influenza
replic
assay
promis
lead
also
inhibit
multipl
adamantinesensit
resist
form
eg
compound
inhibit
virus
major
resist
iav
antivir
like
oseltamivir
andor
synerg
oseltamivir
exhibit
high
genet
barrier
resist
follow
longterm
vitro
passag
support
preclin
paramet
good
stabil
low
toxic
rescu
mice
lethal
infect
go
forward
discoveri
new
chemic
scaffold
andor
optim
exist
lead
medicin
chemistri
may
enabl
emerg
technolog
screen
monitor
conduct
addit
demonstr
clinic
efficaci
new
chemic
lead
remain
achiev
come
decad
like
show
whether
new
inhibitor
significantli
add
evolv
armamentarium
antivir
combat
current
emerg
season
pandem
influenza
strain
fund
provid
canadian
institut
health
research
cihr
grant
number
influenza
antivir
work
wang
laboratori
support
nih
grant
author
declar
conflict
interest
water
shown
sphere
thomaston
et
al
